ATLANTA, April 20, 2015 /PRNewswire/ -- EndoChoice today announced Scott Huennekens has been elevated to the position of Chairman of the Board. Jim Balkcom, who has served as Chairman since 2009 will remain on the Board of Directors and continues to serve as Chairman of the Governance and Compliance Committee.
Under Balkcom's guidance as Chairman, EndoChoice grew from $3 million in revenues in 2009 to more than $61 million in 2014. "Jim Balkcom has been a wonderful partner for the executive team and a tremendous leader for our board," said Mark Gilreath, Founder and CEO of EndoChoice. "Jim's commitment to 'servant leadership' has made a lasting impact on the culture of the company and I look forward to continuing our work together."
"It has been an honor to serve as Chairman during several years of extraordinary company growth," said Jim Balkcom. "We are fortunate to have a leader such as Scott Huennekens to guide our board into the next chapter for EndoChoice."
Mr. Huennekens has served as Chief Executive Officer of Volcano Corporation, a manufacturer of intravascular imaging equipment. From April 2002 to February 2015 he led Volcano from a startup to a public company with annual sales of approximately $400 million. Volcano was acquired in February 2015 by Royal Philips for $1.2 billion. Previously, he served as President and Chief Executive Officer of Digirad Corporation and held senior positions at Baxter International. Mr. Huennekens currently serves as the Chairman of the Board for the Medical Device Manufacturers Association (MDMA).
"EndoChoice is one of the most exciting stories in the medical industry and I'm honored to accept the role of Chairman," said Scott Huennekens. "It's a pleasure to work alongside Jim and Mark and I look forward to supporting the global EndoChoice team."
Based in the Atlanta GA area, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the revolutionary Full Spectrum Endoscopy System (Fuse®). 2014 marked the fifth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com.
EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or [email protected]